Nonpharmacological treatment for patients with nontuberculous mycobacterial lung disease

Cui, Lan; Lai, Sheng-Ru; Chien, Jung-Yien

doi:10.1016/j.jfma.2020.05.013

Cited by 10 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-pharmacological interventions. Beyond antimicrobial therapy, non-pharmacological interventions can contribute to the alleviation of symptoms and improvement in the quality of life of patients with NTM infections, and as such should be a component of the overall management of NTM infections [98] . These interventions include tobacco cessation (where applicable), pulmonary rehabilitation/pulmonary hygiene, exercise programs, and nutritional support.…”

Section: Adjunctive Therapies For Ntm Infectionsmentioning

confidence: 99%

“…Many patients with NTM pulmonary disease also have bronchiectasis and signs of airway mucous plugging. In patients with concomitant bronchiectasis, bronchial hygiene regimens with active airway clearance interventions can be used as adjunctive therapy to theoretically facilitate clearance of NTM and prevent superimposed bacterial infections [4] , [98] . Retrospective data suggests that pulmonary hygiene alone with active surveillance may be appropriate in patients with mild nodular bronchiectatic MAC pulmonary disease.…”

Section: Adjunctive Therapies For Ntm Infectionsmentioning

confidence: 99%

See 1 more Smart Citation

Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease

Pennington

Challener

et al. 2021

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

Non-tuberculous mycobacteria (NTM) is a collective name given to a group of more than 190 species of Mycobacterium . The clinical presentation for most NTM infections is non-specific, often resulting in delayed diagnosis. Further complicating matters is that NTM organisms can be difficult to isolate. Medications used to treat NTM infection can be difficult for patients to tolerate, and prolonged courses of anti-mycobacterial therapy are often required for adequate suppression or eradication. Herein, we review different NTM syndromes, appropriate diagnostic tests, and treatment regimens.

show abstract

Section: Adjunctive Therapies For Ntm Infectionsmentioning

confidence: 99%

Section: Adjunctive Therapies For Ntm Infectionsmentioning

confidence: 99%

Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease

Pennington

Challener

et al. 2021

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

show abstract

“…Education sessions should be tailored to address specific needs of the patients. These sessions should encompass a wide range of topics, including, but not limited to, self-care techniques, exercise training, optimal use of inhalers, airway clearance techniques, infection prevention and management, guidance on oxygen therapy, and nutritional education [ 27 , 29 ].…”

Section: Non-pharmacological Interventionsmentioning

confidence: 99%

“…Although studies are limited, there is increasing evidence that exercise training programs, such as cycling, treadmill workouts, walking, swimming, and resistance training, conducted over a period of 3-8 weeks, enhance exercise capacity, improve health-related quality of life, and reduce dyspnea and risk of exacerbations in patients with bronchiectasis. This intervention is particularly important for patients with diminished exercise capacity, poor health-related quality of life, and dyspnea [ 27 , 28 ].…”

Section: Non-pharmacological Interventionsmentioning

confidence: 99%

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine

Calcagno,

Coppola,

Sarmati

et al. 2024

Infection

View full text Add to dashboard Cite

Background Non-tuberculous mycobacteria (NTM) are generally free-living organism, widely distributed in the environment, with sporadic potential to infect. In recent years, there has been a significant increase in the global incidence of NTM-related disease, spanning across all continents and an increased mortality after the diagnosis has been reported. The decisions on whether to treat or not and which drugs to use are complex and require a multidisciplinary approach as well as patients’ involvement in the decision process. Methods and Results This review aims at describing the drugs used for treating NTM-associated diseases emphasizing the efficacy, tolerability, optimization strategies as well as possible drugs that might be used in case of intolerance or resistance. We also reviewed data on newer compounds highlighting the lack of randomised clinical trials for many drugs but also encouraging preliminary data for others. We also focused on non-pharmacological interventions that need to be adopted during care of individuals with NTM-associated diseases Conclusions Despite insufficient efficacy and poor tolerability this review emphasizes the improvement in patients’ care and the needs for future studies in the field of anti-NTM treatments.

show abstract

“…In vitro evidence suggests tedizolid has concentration-dependent activity against M. avium, and results from a case report demonstrated that tedizolid was used as an alternative treatment in a patient who was diagnosed with NTM-LD caused by MAC and M. kansasii and experienced intolerance to linezolid [128,129]. Other treatment modalities that are being investigated in NTM-LD, with very limited data specifically in MAC-LD, include non-antibiotic interventions such as immunomodulation, hypertonic saline inhalation and other airwayclearance methods, omadacycline, inhaled tigecycline, and mycobacteriophages [130][131][132][133][134][135].…”

Section: Investigational Approaches In Mac-ldmentioning

confidence: 99%

Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments

Ingen

Obradović

Hassan³

et al. 2021

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Introduction: Nontuberculous mycobacterial (NTM) lung disease (LD) is the most common clinical manifestation of NTM infection and is a growing health concern. Up to 85% of NTM-LD cases are caused by Mycobacterium avium complex (MAC). Increased awareness of NTM-LD caused by MAC is needed as patients with this disease experience substantial burden and unmet treatment needs. Areas covered: This review provides clinicians and regulatory and healthcare decision makers an overview of the clinical, economic, and humanistic burden of NTM-LD and the unmet treatment needs faced by patients and clinicians. The review focuses on NTM-LD caused by MAC. A summary of the 2020 NTM guidelines specifically for MAC-LD and an overview of novel treatment options, including amikacin liposome inhalation suspension (ALIS) as the first approved therapy for refractory MAC-LD, and investigational drugs in testing phase are provided. Expert opinion: Key advancements in NTM-LD management include recent updates to clinical practice guidelines, approval of ALIS for the treatment of refractory MAC-LD, and ongoing clinical trials of investigational treatments. Yet opportunities still exist to improve patient outcomes, including development of better screening tools, such as reliable and responsive biomarkers to help identify high-risk patients, and addressing unmet treatment needs.

show abstract

Nonpharmacological treatment for patients with nontuberculous mycobacterial lung disease

Cited by 10 publications

References 48 publications

Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease

Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine

Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments

Contact Info

Product

Resources

About